SE0103613D0 - Novel formulation - Google Patents

Novel formulation

Info

Publication number
SE0103613D0
SE0103613D0 SE0103613A SE0103613A SE0103613D0 SE 0103613 D0 SE0103613 D0 SE 0103613D0 SE 0103613 A SE0103613 A SE 0103613A SE 0103613 A SE0103613 A SE 0103613A SE 0103613 D0 SE0103613 D0 SE 0103613D0
Authority
SE
Sweden
Prior art keywords
pectin
active ingredient
dosage form
pharmaceutically active
alginic acid
Prior art date
Application number
SE0103613A
Other languages
English (en)
Swedish (sv)
Inventor
Jill Ecclestone
Ronnie Paterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103613A priority Critical patent/SE0103613D0/xx
Publication of SE0103613D0 publication Critical patent/SE0103613D0/xx
Priority to PCT/SE2002/001956 priority patent/WO2003037299A1/en
Priority to ES02780231T priority patent/ES2278978T3/es
Priority to US10/493,711 priority patent/US20050037081A1/en
Priority to EP02780231A priority patent/EP1450762B1/en
Priority to DE60217710T priority patent/DE60217710T2/de
Priority to JP2003539643A priority patent/JP2005507408A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0103613A 2001-10-30 2001-10-30 Novel formulation SE0103613D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0103613A SE0103613D0 (sv) 2001-10-30 2001-10-30 Novel formulation
PCT/SE2002/001956 WO2003037299A1 (en) 2001-10-30 2002-10-29 Novel formulation
ES02780231T ES2278978T3 (es) 2001-10-30 2002-10-29 Nueva formulacion.
US10/493,711 US20050037081A1 (en) 2001-10-30 2002-10-29 Novel formulation
EP02780231A EP1450762B1 (en) 2001-10-30 2002-10-29 Novel formulation
DE60217710T DE60217710T2 (de) 2001-10-30 2002-10-29 Neue formulierung
JP2003539643A JP2005507408A (ja) 2001-10-30 2002-10-29 新規製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103613A SE0103613D0 (sv) 2001-10-30 2001-10-30 Novel formulation

Publications (1)

Publication Number Publication Date
SE0103613D0 true SE0103613D0 (sv) 2001-10-30

Family

ID=20285820

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103613A SE0103613D0 (sv) 2001-10-30 2001-10-30 Novel formulation

Country Status (7)

Country Link
US (1) US20050037081A1 (ja)
EP (1) EP1450762B1 (ja)
JP (1) JP2005507408A (ja)
DE (1) DE60217710T2 (ja)
ES (1) ES2278978T3 (ja)
SE (1) SE0103613D0 (ja)
WO (1) WO2003037299A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678817B2 (en) * 2005-06-03 2010-03-16 Medrx Co., Ltd. Enteric medicinal composition for oral use
EP2938348A4 (en) 2012-12-30 2016-07-27 Hadasit Med Res Service ALGINATE COMPOSITIONS AND USES THEREOF
CA2987932C (en) * 2015-06-03 2024-01-16 Ewos Innovation As Oral delivery system for bioactive agents
US11389398B2 (en) 2019-05-14 2022-07-19 Clexio Biosciences Ltd. Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2766124A (en) * 1954-05-25 1956-10-09 American Cyanamid Co Antibiotic-containing ice composition
GB1524740A (en) * 1976-11-09 1978-09-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions for use in the suppression of gastric reflux
US5034378A (en) * 1988-12-15 1991-07-23 James P. Cox Synergistic flavor enhancement nutritional compositions and methods
GB9514438D0 (en) * 1995-07-14 1995-09-13 Danisco Stabilisation process and an enzyme for use in such a process
US5721003A (en) * 1996-03-18 1998-02-24 Kraft Foods, Inc. Foaming coffee creamer and instant hot cappuccino
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6887508B2 (en) * 2002-02-20 2005-05-03 Solae, Llc Protein stabilizing agent

Also Published As

Publication number Publication date
US20050037081A1 (en) 2005-02-17
WO2003037299A1 (en) 2003-05-08
EP1450762B1 (en) 2007-01-17
DE60217710T2 (de) 2007-11-15
JP2005507408A (ja) 2005-03-17
ES2278978T3 (es) 2007-08-16
EP1450762A1 (en) 2004-09-01
DE60217710D1 (de) 2007-03-08

Similar Documents

Publication Publication Date Title
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
EP0966966A3 (en) Nefazodone dosage form
TW200503775A (en) Pharmaceutical composition and method for treating
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
SE0102440D0 (sv) New compound
WO2003047552A3 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
HRP20090022T3 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
CA2417935A1 (en) Anti-inflammatory medicament
SE0103613D0 (sv) Novel formulation
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
WO2006094143A3 (en) Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
ATE319434T1 (de) Pharmazeutische zusammensetzung für die kontrollierte freisetzung eines beta-lactam- antibiotikums
HUP0402093A3 (en) 3-phenyl-2-phenethylthio-propionic acid derivatives as selective agonists of ppar-alpha, their preparation and pharmaceutical compositions containing them
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
EP2022494A3 (en) Laxative preparation containing l-Arginine
IT1306186B1 (it) Sali non igroscopici di principi attivi ad attivita' terapeutica e/onutrizionale e composizioni atte alla somministrazione orale
FR2878443B1 (fr) Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation